Management Board

Our Management Board currently consists of six members. The international composition and the varied responsibilities reflect our global operations.

Helen Giza

Chief Executive Officer

Helen Giza was appointed Chief Executive Officer effective December 6, 2022. She continued to serve as acting Chief Financial Officer until September 30, 2023. Helen Giza joined Ģ��ý in 2019 as Chief Financial Officer and took on the additional role of Chief Transformation Officer heading the FME25 transformation program in 2021. Previously, she has been Chief Integration and Divestiture Management Officer at Takeda Pharmaceuticals since 2018. Before joining the Takeda Corporate Executive Team, she served as Chief Financial Officer of TakedaĢ��ý�s U.S. business unit since 2008. Prior to that she held a number of key international finance and controlling positions, amongst others at TAP Pharmaceuticals and Abbott Laboratories. Helen Giza is a U.K. Chartered Certified Accountant and holds a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois, USA.

CV¹

Craig Cordola, EdD

Care Delivery

Craig Cordola was appointed Chief Executive Officer of Care Delivery and member of the Management Board as of January 1, 2024. Prior to joining Ģ��ý, he served in several Executive roles with Ascension from 2017 through 2023, including, Executive Vice President for Ascension Capital, Executive Vice President and Chief Operating Officer, and President and Chief Executive Officer for Ascension Texas. Craig Cordola joined Ģ��ý in 2024 and has almost 30 years of experience in the healthcare industry, holding Chief Executive Officer roles and other senior leadership positions at several healthcare organizations. He holds an Ed.D. in Leadership and Learning in Organizations from Peabody College at Vanderbilt University, as well as an MHA/MBA from the University of Houston at Clear Lake in the U.S.

CV¹

Martin Fischer

Chief Financial Officer

Martin Fischer was appointed Chief Financial Officer and member of the Management Board as of October 1, 2023. In this role he is responsible for the global finance organization of Ģ��ý. Prior to his appointment, he was Head of Finance for Siemens Healthineers' Diagnostics division based in Tarrytown, NY, USA since 2019. Previously, he headed the Board Office and Organizations function for Siemens Healthineers after leading the business plan and operating model development for the company's initial public offering in March 2018. Earlier in his career, he held a number of key international operational and finance positions in healthcare within Siemens AG. Martin Fischer holds a degree in business informatics from the Reutlingen University of Applied Sciences and an MBA from Friedrich Alexander University, Nuremberg, Germany. He completed the Chief Financial Officer Program at Columbia Business School in New York, USA.

CV¹

Dr. Jörg Häring

Legal, Compliance and Human Resources

Dr. Jörg Häring was appointed Member of the Management Board responsible for Legal, Compliance and Human Resources and Labor Relations Director as of June 1, 2024. Prior to joining Ģ��ý, Dr. Jörg Häring was a member of the Management Committee, Chief Legal & Assurance Officer and Secretary of the Board at the Spanish energy company Compañía Española de Petróleos (CEPSA), overseeing Legal, Corporate Audit, Risk Management, and Compliance globally. He previously spent 18 years with the Siemens Group, including nearly 13 years as General Counsel. Before joining Siemens, he worked at the law firm Cleary, Gottlieb, Steen & Hamilton in Frankfurt, Germany and Brussels, Belgium. Jörg Häring holds a PhD in law and a degree in economics from the University of Tübingen, Germany.

CV¹

Charles Hugh-Jones, MD, FRCP

Medical Office

Charles Hugh-Jones, MD, FRCP, was appointed Global Chief Medical Officer and Member of the Management Board effective January 1, 2026. A leader with extensive prior experience as a biotech CEO, large pharma Chief Medical Officer, and board-certified internal medicine physician, he joined Ģ��ý with transformational leadership experience across multiple therapeutic areas including diabetes, cardiovascular medicine, and oncology. He has worked across all stages of drug development ranging from research, clinical development, medical affairs, data science and commercialization, considering regulatory affairs, drug safety, outcomes research, quality & compliance, and crisis management. In addition to his broad global healthcare industry expertise, he also practiced medicine for seven years in UK academic hospitals.

CV¹

Joseph E. (Joe) Turk

Care Enablement

Joe Turk was appointed Chief Executive Officer of Care Enablement and Management Board member of the Company, responsible for Care Enablement, as of January 1, 2026. Prior to this appointment, he served as Executive Vice President of Global Home and Critical Care Therapies and Head of U.S. Commercial Operations within Care Enablement, Ģ��ýĢ��ý�s MedTech segment. He joined the Company in 2019 following the acquisition of NxStage Medical, Inc. Before, he held positions at Boston Scientific Corporation, McKinsey & Company, Inc. and Deloitte & Touche. Joe Turk holds a Bachelor of Arts in Economics from Wabash College, as well as a Master of Management Degree in Marketing, Finance and Operations from Kellogg School of Management, Northwestern University.

CV¹

¹ CVs are updated on an ongoing basis, but at least once a year.

Ģ��ý